ライフサイエンスコーパス: ZDV

1 ZDV/3TC was associated with a lower rate of clinical tox

2 ZDV/ddI was associated with a lower rate of clinical tox

3 TI pairs: zidovudine (ZDV)/lamivudine (3TC), ZDV/didanosine (ddI), stavudine (d4T)/3TC, d4T/ddI, and

4 FTC-TDF versus 313 (60%) assigned to EFV+3TC-ZDV (HR 0.64, CI 0.54-0.76; p<0.001) and there was a sig

5 ) among 519 participants assigned to EFV+3TC-ZDV (HR 1.51, CI 1.12-2.04; p = 0.007).

6 e hypothesized to be non-inferior to EFV+3TC-ZDV if the upper one-sided 95% confidence bound for the

7 ad similar high efficacy compared to EFV+3TC-ZDV in this trial population, recruited in diverse multi

8 favirenz plus lamivudine-zidovudine (EFV+3TC-ZDV), atazanavir plus didanosine-EC plus emtricitabine (

9 Comparing EFV+FTC-TDF to EFV+3TC-ZDV, during a median 184 wk of follow-up there were 95 t

10 Comparing ATV+DDI+FTC to EFV+3TC-ZDV, during a median follow-up of 81 wk there were 108 f

11 [3TC]/zidovudine [ZDV]/efavirenz [EFV], 3TC/ZDV/nelfinavir [NFV], or other regimens) and studied the

12 Individuals who received 3TC/ZDV/EFV had a more rapid phase 1 viral decay rate than t

13 viral decay rate than those who received 3TC/ZDV/NFV or other regimens.

14 /ZDV/EFV regimen may be more potent than 3TC/ZDV/NFV or other regimens and that early viral dynamics

15 Our findings indicate that the 3TC/ZDV/EFV regimen may be more potent than 3TC/ZDV/NFV or o

16 egimen and 58.8% (95% CI, 47.2%-70.4%) for a ZDV-based regimen; the rate of PEP discontinuation due t

17 g TDF-based PEP (0.3%; 95% CI, 0%-1.1%) vs a ZDV-based regimen (3.2%; 95% CI, 1.5%-4.9%).

18 red abacavir (ABC) plus lamivudine (3TC) and ZDV+3TC as part of a dual or triple first-line antiretro

19 very preterm birth, and neonatal death; and ZDV-3TC-LPV-R was associated with higher risk for preter

20 e consistently lower than BP concentrations, ZDV SP concentrations approximated BP concentrations ear

21 In children, regimens containing ZDV have less toxicity than do those containing d4T, the

22 Overall, regimens containing ZDV were associated with a significantly lower rate of c

23 Short-course ZDV was associated with reduced NVP-resistance mutations

24 inistered sdNVP with or without short-course ZDV were assessed for HIV-1 mutations (K103N, Y181C, G19

25 passive diffusion (APV), slowed elimination (ZDV), and either active accumulation and/or inhibition o

26 +RAL (1.9%; 95% CI, 0%-3.8%) and highest for ZDV+3TC+boosted atazanavir (21.2%; 95% CI, 13.5%-30.0%).

27 , 93.9%; 95% CI, 90.2%-97.7%) and lowest for ZDV+ lamivudine [3TC]+LPV/r (59.1%; 95% CI, 36.2%-82.0%)

28 Among 12 888 children included, ZDV exposure in the first trimester was significantly as

29 Intravenous ZDV remains an effective tool to reduce transmission in

30 Intravenous ZDV was not associated with increased short-term hematol

31 Intravenous ZDV was used in 95.2% of the 11 538 deliveries.

32 In some recent guidelines, intravenous ZDV is no longer systematically recommended for mothers

33 ery were associated with lack of intravenous ZDV (n = 554).

34 We evaluated the impact of intravenous ZDV according to viral load and obstetrical conditions.

35 aracteristics related to lack of intravenous ZDV and compared its association with MTCT rate and othe

36 etrical risk factors, systematic intravenous ZDV appears to be unnecessary.

37 ate was higher without than with intravenous ZDV (7.5% vs 2.9%; P = .01); however, there was no such

38 out intravenous ZDV vs 0.6% with intravenous ZDV; P = .17).

39 ference in MTCT rate (0% without intravenous ZDV vs 0.6% with intravenous ZDV; P = .17).

40 he safety of the regimen containing neonatal ZDV was similar to that of a standard NVP regimen.

41 1.13-1.52); zidovudine, lamivudine, and NPV (ZDV-3TC-NVP) (647 of 1365 [47.4%]; ARR, 1.30; 95% CI, 1.

42 We conclude that the combination of ZDV, 3TC, and LPV/r is able to provide efficient and dur

43 se of NVP or NVP (same dose) plus 4 mg/kg of ZDV twice per day for a week.

44 s of an M41L/T215Y mutant in the presence of ZDV, introduction of this mutation into a D67N/K70R/K219

45 d increased viral fitness in the presence of ZDV.

46 T215F mutants in the absence or presence of ZDV.

47 ty were tested in the absence or presence of ZDV.

48 ity than did wild-type HIV-1 over a range of ZDV concentrations, but T215F mutants had only a modest

49 ths postpartum, with no differences based on ZDV use (logrank P = .99).

50 5 [47.4%]; ARR, 1.30; 95% CI, 1.20-1.41); or ZDV-3TC-LPV-R (75 of 167 [44.9%]; ARR, 1.21; 95% CI, 1.0

51 )/zidovudine (ZDV)/lamivudine (3TC), IDV, or ZDV/3TC.

52 domly assigned to NVP (n = 448) and NVP plus ZDV (n = 446).

53 0.1% (45/444) in those administered NVP plus ZDV (P =.30).

54 12.7%-19.8%) in those who received NVP plus ZDV (P =.36).

55 6.9% (25/363) in those who received NVP plus ZDV (P =.88).

56 equent when infants had received SD-NVP plus ZDV and mothers had not received SD-NVP than when infant

57 ) in infants receiving NVP only and NVP plus ZDV, respectively (P =.76).

58 y one of the seven women who did not receive ZDV was a transmitter, for an overall vertical transmiss

59 Infants received ZDV and 3TC for 6 weeks and a single dose of oral d4T at

60 ns were associated with higher risk for SGA; ZDV-3TC-NVP was associated with higher risk of stillbirt

61 This review supports ZDV+3TC+LPV/r as the preferred 3-drug regimen for PEP in

62 tum NVP-resistance was lower among 31 taking ZDV+sdNVP compared to 33 taking only sdNVP (35.5% vs. 72

63 or without 3TC is a potential alternative to ZDV for HIV-infected pregnant women.

64 fic association between in utero exposure to ZDV and CHDs, and a long-lasting postnatal myocardial re

65 ts, girls (but not boys) exposed in utero to ZDV/lamivudine/ritonavir-boosted lopinavir (LPV/r) had a

66 igher rate of laboratory toxicities than was ZDV/ddI.

67 rruption of therapy or in those treated with ZDV/3TC alone, who had viral loads in their lymph nodes

68 Short-course zidovudine (ZDV) was hypothesized to lower rates of NVP-resistance.

69 orted outcomes of children given zidovudine (ZDV) plus lamivudine (3TC) as a 2-drug PEP regimen.

70 d 36-52 weeks of indinavir (IDV)/zidovudine (ZDV)/lamivudine (3TC), IDV, or ZDV/3TC.

71 c function have been reported in zidovudine (ZDV)-exposed uninfected children.

72 viral therapy (HAART), including zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV), and found a

73 odeficiency virus (HIV)-infected zidovudine (ZDV)-intolerant/refusing pregnant women and of single-do

74 Intrapartum intravenous zidovudine (ZDV) prophylaxis is a long-standing component of prevent

75 50) evaluated the penetration of zidovudine (ZDV), lamivudine (3TC), and amprenavir (APV), given alon

76 of the 5 most common NRTI pairs: zidovudine (ZDV)/lamivudine (3TC), ZDV/didanosine (ddI), stavudine (

77 the HIV-positive women received zidovudine (ZDV) as prophylaxis against HIV vertical transmission; o

78 -NVP, and some randomly received zidovudine (ZDV) as well.

79 Resistance to zidovudine (ZDV) results from thymidine analog resistance mutations

80 IV-1 and HIV-2, all treated with zidovudine (ZDV), lamivudine (3TC), and lopinavir-ritonavir (LPV/r),

81 erapy regimens (lamivudine [3TC]/zidovudine [ZDV]/efavirenz [EFV], 3TC/ZDV/nelfinavir [NFV], or other

82 information on 2-drug regimens (zidovudine [ZDV]- or tenofovir [TDF]-based regimens), and 10 studies